Dietary Supplementation with Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability

Summary

In a placebo-controlled trial healthy volunteers and patients with hyperlipoproteinemias types II and IV received orally vitamin E at doses of 300 mg and 600 mg daily for 2 weeks. Serum tocopherol levels increased two-fold, but serum concentrations of total lipids, cholesterol, triglycerides, ceruloplasmin and transferrin remained unchanged. Dietary supplementation with vitamin E suppressed elevated concentrations of plasma lipid peroxides and this effect was correlated with an increase in serum antioxidant activity. In patients a mild platelet suppressant effect of vitamin E (600 mg daily) was observed.

Feeding an atherogenic diet to rabbits for a week resulted in elevation of plasma lipid peroxides and a 90% decrease in arterial generation of prostacyclin. Enrichment of the atherogenic diet with 100 mg vitamin E daily prevented the increase in plasma lipid peroxides and protected the prostacyclin generating system in arteries. Thus, in hyperlipoproteinemias vitamin E corrects certain abnormalities of lipid metabolism which might predispose to atherosclerosis.

Keywords

Vitamin E - Hyperlipoproteinemias - Lipid peroxides - Prostacyclin - Atherosclerosis

• References

• 1 Gryglewski RJ, Szczeklik A. Inhibition of prostacyclin formation by lipid peroxides in the arterial wall: hypothetical step in development of atherosclerosis. Materia Med Pol 1978; 37: 338-341
• 2 Dormandy TL. Free radical oxidation and antioxidants. Lancet 1978; 1: 647-650
• 3 Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976; 12: 685-713
• 4 Salmon JA, Smith DR, Flower RJ, Moncada S, Vane JR. Further studies on the enzymic conversion of prostaglandins endoperoxides into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta 1978; 523: 250-258
• 5 Kulmacz RJ, Lands EM. Characteristics of prostaglandin H synthase. In: Advances in Prostaglandins and Thromboxane Leukotriene Research. Samuelsson B, Paoletti R, Ramwell PW. (Eds.) 93 Raven Press; New York: 1983
• 6 Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 37-43
• 7 Sato Y, Hotta N, Sakamato N, Matsuoka S, Ohishi N, Yagi K. Lipid peroxide levels in plasma of diabetic patients. Biochem Med 1979; 21: 104-109
• 8 Glavind J, Hartman S, Clemensen J, Jessen EK, Dam H. Studies on the role of lipid peroxides in human pathology. II. The presence of peroxidized lipids in the atherosclerosis aortas. Acta Pathol Microbiol Scand 1952; 30: 1-10
• 9 Gryglewski RJ, Dembinska-Kieć A, Chytkowski A, Gryglewska T. Prostacyclin and thromboxane biosynthetic capacities of the heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978; 31: 385-394
• 10 Larrue J, Rigaud M, Daret D, Demond J, Durand J, Bricaud H. Prostacyclin production by cultured smooth muscle cells from atherosclerotic rabbit aorta. Nature 1980; 285: 480-482
• 11 D’Angelo V, Villa S, Myśliwiec M, Donati MB, de Gaetano G. Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemostas 1978; 39: 535-536
• 12 Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
• 13 Joist JH, Baker RK, Schonfeld G. Increased in vivo and in vitro platelet function in type II-and type IV-hyperlipoprotenemia. Thromb Res 1979; 15: 95-108
• 14 Szczeklik A, Gryglewski RJ, Musial J, Grodzińska L, Serwońska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemostas 1978; 40: 66-74
• 15 Dembińska-Kiecć A, Żmuda A, Grodzińska L, Bieroń K, Basista M, Kostka-Trabka E, Telesz E, Żelazny T. Increased platelet activity after termination of prostacyclin infusion in man. Prostaglandins 1981; 21: 827-833
• 16 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 923-926
• 17 Stocks J, Gutteridge JMC, Sharp RJ, Dormandy TL. Assay using brain homogenate for measuring the antioxidant activity of biological fluids. Clin Sci Molec Med 1974; 47: 215-222
• 18 Ostrowski J, Hertel Z. Spectrofluorimetric determination of serum tocopherol (in Polish). Diagn Lab 1977; 13: 163-166
• 19 Frigs CS, Dunn RT. A colorometric method for determination of total serum lipids based on the sulpho-phospho-vanilin reaction. Am J Clin Pathol 1970; 53: 89-95
• 20 Machlin LJ, Gabriel E. Kinetics of tissue α-tocopherol uptake and depletion following administration of high levels of vitamin E. Ann N Y Acad Sci 1982; 393: 48-60
• 21 Baker H, Frank O, De Angelis B, Feingold S. Plasma tocopherol in man at various times after ingesting free acetylated tocopherol. Nutr Rep Int 1980; 21: 531-535
• 22 Steiner M. Effect of alpha-tocopherol administration on platelet function in man. Thromb Haemostas 1983; 49: 73-77
• 23 Burton GW, Joyce A, Ingold KU. First proof that vitamin E is major lipid-soluble, chain-breaking antioxidant in human plasma. Lancet 1983; 2: 327
• 24 Vidlakova M, Erazimova J, Horky J, Placer Z. Relationship of serum antioxidative activity to tocopherol and serum inhibitor of lipid peroxidation. Clin Chim Acta 1972; 36: 61-66
• 25 Cranfield LM, Gollan JL, White AG, Dormandy TL. Serum antioxidant activity in normal and abnormal subjects. Ann Clin Biochem 1979; 16: 299-306
• 26 Saeed SA, Drew M, Collier HOJ. Endogenous inhibitors of lipoxygenase. Eur J Pharm 1980; 67: 169-170
• 27 Agradi E, Petroni A, Sacini C, Galli C. In vitro effect of synthetic antioxidants and vitamin E on arachidonic acid metabolism and thromboxane formation in human platelets and on platelet generation. Prostaglandins 1981; 22: 255-264
• 28 Chan AC, Leith MK. Decreased prostacyclin synthesis in vitamin E-deficient rabbit aorta. Am J Clin Nutr 1981; 34: 2341-2347
• 29 Okuma M, Takayama H, Uchino H. Generation of prostacyclin-like substance and lipid peroxidation in vitamin E-deficient rats. Prostaglandins 1980; 19: 527-536
• 30 Panganamala RV, Cornvell DG. The effects of vitamin E on arachidonic acid metabolism. Ann N Y Acad Sci 1982; 393: 376-383
• 31 Chan AC, Pritchard ET, Choy PC. Differential effects of dietary vitamin E and antioxidants on eicosanoid synthesis in young rabbits. J Nutr 1983; 113: 813-819
• 32 Mower R, Steiner M. Biochemical interaction of arachidonic acid and vitamin E in human platelets. Prostagl Leukotr Med 1983; 10: 389-403
• 33 Fitzgerald GA, Brash AR. Endogenous prostacyclin and thromboxane biosynthesis during chronic vitamin E therapy in man. In: Vitamin E: Biochemical, Hematological and Clinical Aspects. Ann N Y Acad Sci 1982; 393: 209-211
• 34 Szczeklik A, Gryglewski RJ. Low density lipoproteins (LDL) are carriers for lipid peroxides and inhibit prostacyclin (PGI₂) biosynthesis in arteries. Artery 1980; 7: 488-495
• 35 Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883-3887
• 36 Nordøy A, Svensson B, Wiebe D, Hoak JC. Lipoproteins and the inhibitory effect of human endothelial cells on platelet function. Circ Res 1978; 43: 527-534
• 37 Szczeklik A, Gryglewski RJ, Domagala B, Zmuda A, Hartwich J, Woźny E, Grzywacz M, Madej J, Gryglewska T. Serum lipoproteins, lipid peroxides and prostacyclin biosynthesis in patients with coronary heart disease. Prostaglandins 1981; 22: 795-807
• 38 Henriksen T, Evensen SA, Torsvik H, Corlander B. Human endothelial cells in primary culture. Effects of normal lipoproteins on the incorporation of acetate into lipidis. Biochim Biophys Acta 1977; 489: 64-71
• 39 Evensen SA, Gaidai KJ, Nilsen E. LDL-induced cytotoxicity and its inhibition by anti-oxidant treatment in cultured human endothelial cells and fibroblasts. Atherosclerosis 1983; 49: 23-30
• 40 Peng SK, Taylor CB, Mosbach EH, Huang WY, Hill J, Mikkelson B. Distribution of 25-hydroxy-cholesterol in plasma lipoproteins and its role in atherogenesis. Atherosclerosis 1982; 41: 395-402
• 41 Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte macrophages. Proc Natl Acad Sci USA 1980; 77: 2214-2218
• 42 Hessler JR, Robertson AL, Chisolm GL. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32: 213-218
• 43 Nordøy A. Platelets and fatty acids. Biochem Exp Biol 1975; 11: 295-305
• 44 Vatassery GT, Krezowski AM, Eckfeld JH. Vitamin E concentrations in human blood plasma and platelets. Am J Clin Nutr 1983; 77: 1020-1024